The presence of antiplatelet antibodies against GPIIb, which may be a chronic effect of immune thrombocytopenia caused by bevacizumab (a drug with a half-life of 10 days) could be the reason for this. This evidence concerns the gene ITGA2B and autoimmune thrombocytopenic purpura.